• 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 205-249.
  • 2
    European Society of Medical Oncology. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. 2007; 18: ii5-ii8.
  • 3
    Basuyau J, Blanc-Vincent M, Bidart J, et al. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000. Br J Cancer. 2003; 89: S32-S34.
  • 4
    Molina R, Barak V, Van Dalen A, et al. Tumor markers in breast cancer—European Group on tumor markers recommendations. Tumor Biol. 2005; 26: 281-293.
  • 5
    Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007: update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5291.
  • 6
    Lu W, Schaapveld M, Jansen L, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009; 45: 3000-3007.
  • 7
    Lonneux M, Borbath II, Berliere M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging. 2000; 3: 45-49.
  • 8
    Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer. 2001; 2: 229-234.
  • 9
    Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002; 46: 113-121.
  • 10
    Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38: 250-256.
  • 11
    Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003; 129: 147-153.
  • 12
    Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging. 2004; 31: 179-188.
  • 13
    Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006; 107: 2545-2551.
  • 14
    Veit-Haibach P, Antoch G, Beyer T, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007; 80: 508-515.
  • 15
    Haug AR, Schmidt GP, Klingenstein A, et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr. 2007; 31: 629-634.
  • 16
    Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005; 90: 105-112.
  • 17
    Khatcheressian J, Wolff A, Smith T, et al. American Society of Clinical Oncology 2006: Update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24: 5091-5097.
  • 18
    Saad A, Kanate A, Sehbai A, Marano G, Hobbs G, Abraham J. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. Clin Breast Cancer. 2008; 8: 357-361.
  • 19
    Schneider E. Multi-marker testing for cancer: what can we learn from modern prenatal testing for trisomy-21. Cancer Informatics. 2006; 2: 44-47.
  • 20
    Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET/CT imaging on the decision making in biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008; 108: 160-165.
  • 21
    Aide N, Huchet V, Switsers O, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun. 2007; 28: 267-272.
  • 22
    Dirisamer A, Halpern BS, Flory D, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol. 2010; 73: 294-299.
  • 23
    Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002; 29: 1317-1323.
  • 24
    Avril N, Rose C, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000; 18: 3495-3502.
  • 25
    Aliaga A, Rousseau J, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2- [F-18]fluoro-d-glucose in murine models of breast cancer. Mol Imaging Biol. 2007; 9: 144-150.
  • 26
    Zervoudis S, Peitsidis P, Iatrakis G, et al. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON. 2007; 12: 487-492.
  • 27
    Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Ann Oncol. 2009; 20: 1913-1927.
  • 28
    Molina R, Jo J, Filella X, et al. C-erbB-2, CEA and CA 15-3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999; 19: 2551-2555.
  • 29
    Nishimura R, Nagao K, Miyayama H, et al. Elevated serum CA 15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer. 2003; 10: 220-227.
  • 30
    Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16: 3375-3379.
  • 31
    Du Y, Cullum I, Illidge T, Ell P. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007; 25: 3440-3447.
  • 32
    Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008; 33: 97-101.
  • 33
    Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol. 2008; 65: 47-58.
  • 34
    Aukema T, Rutgers E, Vogel W, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur J Surg Oncol. 2010; 36: 387-392.
  • 35
    The GIVIO investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA. 1994; 271: 1587-1592.
  • 36
    Rosselini Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial—National Research Council Project on Breast Cancer Follow-up. JAMA. 1994; 271: 1593-1597.
  • 37
    Joseph E, Hyacinthe M, Lyman G, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol. 1998; 5: 522-528.